Gilead Sciences can only produce so much of its newly authorized COVID-19 med remdesivir, so it’s scouting other companies to bolster global supply. The Big Biotech is in licensing talks with major players, including generics makers in India and Pakistan,
read moreThe Scottish government has given funds £101,903 to support the project More: Aberdeen Uni proceeds with COVID-19 mass screening research Source: News
read moreThe closing of the acquisition remains subject to other customary closing conditions More: US regulators permit AbbVie/Allergan merger Source: News
read moreThe guideline is designed to help healthcare professionals who are not kidney specialists to prevent, detect and manage AKI in hospitalised patients with suspected or confirmed COVID-19 More: NICE publishes rapid COVID-19 guideline for acute kidney injury Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals